Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies

Nature Biotechnology

Volumn 24, Issue 12, 2006, Pages 1551-1557

  Hancock, Robert E W ^a   Sahl, Hans Georg ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Inst Med Mikrobiol Pharmazeut   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; COST EFFECTIVENESS; DRUG PRODUCTS; DRUG THERAPY; IMMUNOLOGY; PROTEINS; TOXICITY;

ANTIMICROBIAL DRUGS; CLINICAL TRIALS; IMMUNOMODULATORY ACTIVITIES; THERAPEUTIC STRATEGIES;

BIOTECHNOLOGY;

ALPHA DEFENSIN; BACTERIOCIN; BETA DEFENSIN; BL 2060; BPI 23; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHYMOTRYPSIN; CLS 001; COLISTIMETHATE; COLISTIN; CP 226; CPG OLIGODEOXYNUCLEOTIDE; CSA 13; CZEN 002; DAPTOMYCIN; GALLIDERMIN; GRAMICIDIN S; HB 107; HB 50; HLF 1 11; IB 367; IMX 942; INDOLICIDIN; MERSACIDIN; METICILLIN; MX 226; NISIN; OFLOXACIN; OMIGANAN; PAC 113; PEXIGANAN ACETATE; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; PTX 002; PTX 005; PTX 006; PTX 007; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CATHETER INFECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC FOOT; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; ENZYME DEGRADATION; GRAM POSITIVE BACTERIUM; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTOXICITY; IMPETIGO; INFLAMMATION; INNATE IMMUNITY; LARGE SCALE PRODUCTION; NONHUMAN; ORAL MUCOSAL DISEASE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SEPSIS; SKIN INFECTION;

ANTI-INFECTIVE AGENTS, LOCAL; ANTIMICROBIAL CATIONIC PEPTIDES; CLINICAL TRIALS; DRUG DESIGN;

BACTERIA (MICROORGANISMS);

EID: 33845699790     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1267     Document Type: Review

References (40)

1. Hancock, R.E.W. & Lehrer, R. Cationic peptides: a new source of antibiotics. Trends Biotechnol. 16, 82-88 (1998).
2. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389-395 (2002).
3. Oppenheim, J.J. & Yang, D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359-365 (2005).
4. Bowdish, D.M.E., Davidson, D.J. & Hancock, R.E.W. A re-evaluation of the role of host defense peptides in mammalian immunity. Curr. Protein Pept. Sci. 6, 35-51 (2005).
5. http://www.bbcm.univ.trieste.it/~tossi/amsdb.html
6. Emes, R.D., Goodstadt, L., Winter, E.E. & Ponting, C.P. Comparison of the genomes of human and mouse lays the foundation of genome zoology. Hum. Mol. Genet. 12, 701-709 (2003).
7. Patil, A., Hughes, A.L. & Zhang, G. Rapid evolution and diversification of mammalian alpha-defensins as revealed by comparative analysis of rodent and primate genes. Physiol. Genomics 20, 1-11 (2004).
8. Crovella, S. et al. Primate beta-defensins - structure, function and evolution. Curr. Protein Pept. Sci. 6, 7-21 (2005).
9. Peschel, A. & Sahl, H.G. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 4, 529-536 (2006).
10. Yount, N.Y. & Yeaman M.R. Structural congruence among membrane-active host defense polypeptides of diverse phylogeny. Biochim. Biophys. Acta 9, 1373-1386 (2006).
11. McAuliffe, O., Ross, R.P. & Hill, C. Lantibiotics: structure, biosynthesis and mode of action. FEMS Microbiol. Rev. 25, 285-308 (2001).
12. Hsu, S.T. et al. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 11, 963-967 (2004).
13. Finking, R. & Marahiel, M.A. Biosynthesis of nonribosomal peptides. Annu. Rev. Microbiol. 58, 453-488 (2004).
14. Coulter, S.N. et al. Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments. Mol. Microbiol. 30, 393-404 (1998).
15. Jenssen, H., Hamill, P. & Hancock, R.E.W. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491-511 (2006).
16. Yeaman, M.R. & Yount, N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55, 27-55 (2003).
17. Sahl, H.G. et al. Mammalian defensins: structures and mechanism of antibiotic activity. J. Leukoc. Biol. 77, 466-475 (2005).
18. Brazas, M.D. & Hancock, R.E.W. Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance. Drug Discov. Today 10, 1245-1252 (2005).
19. Perron, G.G., Zasloff, M. & Bell, G. Experimental evolution of resistance to an anti microbial peptide. Proc. Biol. Sci. 273, 251-256 (2006).
20. Samuelsen, O. et al. Induced resistance to the antimicrobial peptide lactoferricin B in Staphylococcus aureus. FEBS Lett. 579, 3421-3426 (2005).
21. Breukink, E. & de Kruijff, B. Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 5, 321-332 (2006).
22. Zhang, L. & Falla, T.J. Antimicrobial peptides: therapeutic potential. Expert Opin. Pharmacother. 7, 653-663 (2006).
23. Lau, Y.E. et al. Interaction and cellular localization of the human host defense peptide, LL-37, with lung epithelial cells. Infect. Immun. 73, 583-591 (2005).
24. Sandgren, S. et al. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J. Biol. Chem. 279, 17951-17956 (2004).
25. McPhee, J.B., Scott, M.G. & Hancock, R.E.W. Design of host defence peptides for antimicrobial and immunity enhancing activities. Comb. Chem. High Throughput Screen. 8, 257-272 (2005).
26. Mygind, P.H. et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437, 975-980 (2005).
27. Cotter, P.D., Hill, C. & Ross, R.P. Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 3, 777-788 (2005).
28. Hilpert, K., Volkmer-Engert, R., Walter, T. & Hancock, R.E.W. High-throughput generation of small antibacterial peptides with improved activity. Nat. Biotechnol. 23, 1008-1012 (2005).
29. Blondelle, S.E. & Houghten, R.A. Novel antimicrobial compounds identified using synthetic combinatorial library technology. Trends Biotechnol. 14, 60-65 (1996).
30. Freidinger, R.M. et al. Design and synthesis of novel bioactive peptides and peptidomimetics. J. Med. Chem. 46, 5553-5566 (2003).
31. Masip, I., Perez-Paya, E. & Messeguer, A. Peptoids as source of compounds eliciting antibacterial activity. Comb. Chem. High Throughput Screen. 8, 235-239 (2005).
32. Robinson, J.A. et al. Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. Bioorg. Med. Chem. 13, 2055-2064 (2005).
33. Porter, E.A., Wang, X., Lee, H.S., Weisblum, B. & Gellman, S.H. Non-haemolytic beta-amino-acid oligomers. Nature 404, 565 (2000).
34. Marshall, N.J., Andruszkiewicz, R., Gupta, S., Milewski, S. & Payne, J.W. Structure-activity relationships for a series of peptidomimetic antimicrobial prodrugs containing glutamine analogues. J. Antimicrob. Chemother. 51, 821-831 (2003).
35. Xie, L. et al. Lacticin 481: in vitro reconstitution of lantibiotic synthetase activity. Science 303, 679-681 (2004).
36. Rink, R., et al. Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes. Biochem. 44, 8873-8882 (2005).
37. Finlay, B.B. & Hancock, R.E.W. Can innate immunity be enhanced to treat infections? Nat. Rev. Microbiol. 2, 497-504 (2004).
38. O'Neill, L.A. How Toll-like receptors signal: what we know and what we don't know. Curr. Opin. Immunol. 18, 3-9 (2006).
39. Bowdish, D.M.E. et al. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77, 451-459 (2005).
40. Zhang, L. et al. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob. Agents Chemother. 49, 2921-2927 (2005).